Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry

Richard M. Trosch, Alberto J. Espay, Daniel Truong, Ramon Gil, Carlos Singer, Peter A. LeWitt, Mark F. Lew, Michele Tagliati, Charles Howard Adler, Jack J. Chen, Dominic Marchese, Cynthia L. Comella

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background The ANCHOR-CD prospective observational registry study evaluated the effectiveness of abobotulinumtoxinA in adult idiopathic cervical dystonia (CD) in clinical practice. Methods Adults with CD were eligible. Treating physicians determined abobotulinumtoxinA dose and treatment interval. The primary endpoint was patient response rate (Toronto Western Spasmodic Torticollis Rating Scale [TWSTRS] score reduction ≥ 25% and Patient Global Impression of Change [PGIC] score of + 2 or + 3 at Week 4 of Cycle 1). Results 350 patients enrolled (75% women; mean age 59 ± 13.6 years; 27.4% botulinum neurotoxin-naive) and 347 received at least 1 treatment. The median abobotulinumtoxinA dose for Cycle 1 was 500 Units. At Week 4, the responder rate was 30.6% (n = 304) and the TWSTRS total score decreased 27.4% from baseline. PGIC of at least “Much improved” was documented in 43.6% of patients and maintained in Cycles 2 through 4 (43.3%, 48.9%, and 52.8%, respectively). A total of 39 adverse events (31 study drug-related) were reported in 17 patients (5%); the most common were dysphagia (n = 6), muscle weakness (n = 4), and neck pain (n = 3). Conclusion This study confirmed the beneficial effect of abobotulinumtoxinA on CD in routine clinical practice as measured by improvements in TWSTRS and PGIC. No new safety concerns were identified.

Original languageEnglish (US)
Pages (from-to)84-90
Number of pages7
JournalJournal of the Neurological Sciences
Volume376
DOIs
StatePublished - May 15 2017

Fingerprint

Torticollis
Neurotoxins
Multicenter Studies
Observational Studies
Registries
Neck Pain
Muscle Weakness
Deglutition Disorders
abobotulinumtoxinA
Physicians
Safety
Therapeutics
Pharmaceutical Preparations

Keywords

  • AbobotulinumtoxinA
  • Botulinum toxin
  • Cervical dystonia
  • Cervical pain
  • Disability
  • Torticollis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia : The ANCHOR-CD registry. / Trosch, Richard M.; Espay, Alberto J.; Truong, Daniel; Gil, Ramon; Singer, Carlos; LeWitt, Peter A.; Lew, Mark F.; Tagliati, Michele; Adler, Charles Howard; Chen, Jack J.; Marchese, Dominic; Comella, Cynthia L.

In: Journal of the Neurological Sciences, Vol. 376, 15.05.2017, p. 84-90.

Research output: Contribution to journalArticle

Trosch, RM, Espay, AJ, Truong, D, Gil, R, Singer, C, LeWitt, PA, Lew, MF, Tagliati, M, Adler, CH, Chen, JJ, Marchese, D & Comella, CL 2017, 'Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry', Journal of the Neurological Sciences, vol. 376, pp. 84-90. https://doi.org/10.1016/j.jns.2017.02.042
Trosch, Richard M. ; Espay, Alberto J. ; Truong, Daniel ; Gil, Ramon ; Singer, Carlos ; LeWitt, Peter A. ; Lew, Mark F. ; Tagliati, Michele ; Adler, Charles Howard ; Chen, Jack J. ; Marchese, Dominic ; Comella, Cynthia L. / Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia : The ANCHOR-CD registry. In: Journal of the Neurological Sciences. 2017 ; Vol. 376. pp. 84-90.
@article{661c30f4dc8344628665a4be6d835b9b,
title = "Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry",
abstract = "Background The ANCHOR-CD prospective observational registry study evaluated the effectiveness of abobotulinumtoxinA in adult idiopathic cervical dystonia (CD) in clinical practice. Methods Adults with CD were eligible. Treating physicians determined abobotulinumtoxinA dose and treatment interval. The primary endpoint was patient response rate (Toronto Western Spasmodic Torticollis Rating Scale [TWSTRS] score reduction ≥ 25{\%} and Patient Global Impression of Change [PGIC] score of + 2 or + 3 at Week 4 of Cycle 1). Results 350 patients enrolled (75{\%} women; mean age 59 ± 13.6 years; 27.4{\%} botulinum neurotoxin-naive) and 347 received at least 1 treatment. The median abobotulinumtoxinA dose for Cycle 1 was 500 Units. At Week 4, the responder rate was 30.6{\%} (n = 304) and the TWSTRS total score decreased 27.4{\%} from baseline. PGIC of at least “Much improved” was documented in 43.6{\%} of patients and maintained in Cycles 2 through 4 (43.3{\%}, 48.9{\%}, and 52.8{\%}, respectively). A total of 39 adverse events (31 study drug-related) were reported in 17 patients (5{\%}); the most common were dysphagia (n = 6), muscle weakness (n = 4), and neck pain (n = 3). Conclusion This study confirmed the beneficial effect of abobotulinumtoxinA on CD in routine clinical practice as measured by improvements in TWSTRS and PGIC. No new safety concerns were identified.",
keywords = "AbobotulinumtoxinA, Botulinum toxin, Cervical dystonia, Cervical pain, Disability, Torticollis",
author = "Trosch, {Richard M.} and Espay, {Alberto J.} and Daniel Truong and Ramon Gil and Carlos Singer and LeWitt, {Peter A.} and Lew, {Mark F.} and Michele Tagliati and Adler, {Charles Howard} and Chen, {Jack J.} and Dominic Marchese and Comella, {Cynthia L.}",
year = "2017",
month = "5",
day = "15",
doi = "10.1016/j.jns.2017.02.042",
language = "English (US)",
volume = "376",
pages = "84--90",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia

T2 - The ANCHOR-CD registry

AU - Trosch, Richard M.

AU - Espay, Alberto J.

AU - Truong, Daniel

AU - Gil, Ramon

AU - Singer, Carlos

AU - LeWitt, Peter A.

AU - Lew, Mark F.

AU - Tagliati, Michele

AU - Adler, Charles Howard

AU - Chen, Jack J.

AU - Marchese, Dominic

AU - Comella, Cynthia L.

PY - 2017/5/15

Y1 - 2017/5/15

N2 - Background The ANCHOR-CD prospective observational registry study evaluated the effectiveness of abobotulinumtoxinA in adult idiopathic cervical dystonia (CD) in clinical practice. Methods Adults with CD were eligible. Treating physicians determined abobotulinumtoxinA dose and treatment interval. The primary endpoint was patient response rate (Toronto Western Spasmodic Torticollis Rating Scale [TWSTRS] score reduction ≥ 25% and Patient Global Impression of Change [PGIC] score of + 2 or + 3 at Week 4 of Cycle 1). Results 350 patients enrolled (75% women; mean age 59 ± 13.6 years; 27.4% botulinum neurotoxin-naive) and 347 received at least 1 treatment. The median abobotulinumtoxinA dose for Cycle 1 was 500 Units. At Week 4, the responder rate was 30.6% (n = 304) and the TWSTRS total score decreased 27.4% from baseline. PGIC of at least “Much improved” was documented in 43.6% of patients and maintained in Cycles 2 through 4 (43.3%, 48.9%, and 52.8%, respectively). A total of 39 adverse events (31 study drug-related) were reported in 17 patients (5%); the most common were dysphagia (n = 6), muscle weakness (n = 4), and neck pain (n = 3). Conclusion This study confirmed the beneficial effect of abobotulinumtoxinA on CD in routine clinical practice as measured by improvements in TWSTRS and PGIC. No new safety concerns were identified.

AB - Background The ANCHOR-CD prospective observational registry study evaluated the effectiveness of abobotulinumtoxinA in adult idiopathic cervical dystonia (CD) in clinical practice. Methods Adults with CD were eligible. Treating physicians determined abobotulinumtoxinA dose and treatment interval. The primary endpoint was patient response rate (Toronto Western Spasmodic Torticollis Rating Scale [TWSTRS] score reduction ≥ 25% and Patient Global Impression of Change [PGIC] score of + 2 or + 3 at Week 4 of Cycle 1). Results 350 patients enrolled (75% women; mean age 59 ± 13.6 years; 27.4% botulinum neurotoxin-naive) and 347 received at least 1 treatment. The median abobotulinumtoxinA dose for Cycle 1 was 500 Units. At Week 4, the responder rate was 30.6% (n = 304) and the TWSTRS total score decreased 27.4% from baseline. PGIC of at least “Much improved” was documented in 43.6% of patients and maintained in Cycles 2 through 4 (43.3%, 48.9%, and 52.8%, respectively). A total of 39 adverse events (31 study drug-related) were reported in 17 patients (5%); the most common were dysphagia (n = 6), muscle weakness (n = 4), and neck pain (n = 3). Conclusion This study confirmed the beneficial effect of abobotulinumtoxinA on CD in routine clinical practice as measured by improvements in TWSTRS and PGIC. No new safety concerns were identified.

KW - AbobotulinumtoxinA

KW - Botulinum toxin

KW - Cervical dystonia

KW - Cervical pain

KW - Disability

KW - Torticollis

UR - http://www.scopus.com/inward/record.url?scp=85014854661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014854661&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2017.02.042

DO - 10.1016/j.jns.2017.02.042

M3 - Article

C2 - 28431634

AN - SCOPUS:85014854661

VL - 376

SP - 84

EP - 90

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

ER -